Thyas has joined joint research initiated by The Center for iPS Cell Research and Application, Kyoto University (CiRA) and KOTAI Biotechnologies, Inc., on personalized cancer immunotherapy using regenerated T cells derived from induced pluripotent stem cells.

Click here for more details.